Stoke Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Stoke Therapeutics

10/03/2022 14:18

* Stoke Therapeutics Inc  STOK.OQ  reported a quarterly
adjusted
loss of 66 cents​​ per share for the quarter ended in December.
The mean expectation of ten analysts for the quarter was for a
loss of 62 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Stoke Therapeutics Inc's reported EPS for the quarter was
a loss
of 66 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Stoke Therapeutics Inc shares had fallen by 13.4% this
quarter.
    * The company reported a quarterly loss of $24.45 million.
    * Wall Street's median 12-month price target for Stoke
Therapeutics Inc is $61.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 10 at 02:18 p.m.  ​All
figures in US dollars unless otherwise stated